Clinical trials: RANDOMIZED
Acute Bronchitis
A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases
To evaluate the clinical efficacy and safety in patients with Acute Bronchitis or Secondary Infection of Chronic Respiratory Diseases receiving a dose of 2 g of azithromycin in the SR formulation.
- Trial name
- NCT00360464
- Testing
- Azithromycin SR
- Where
- 19 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Pfizer
Healthy Volunteers (HV), Parkinson's Disease (PD)
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD).
- Trial name
- NCT07310264
- Testing
- VT-5006
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Vertero Therapeutics
Diabetic Foot Ulcer
Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.
This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Wagner grade 2 Foot Ulcer, compared to placebo therapy.
- Trial name
- NCT04569409
- Testing
- ALLO-ASC-DFU, Vehicle Sheet
- Where
- 5 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Anterogen Co., Ltd.
Healthy Volunteers, Autoimmune Disease
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
- Trial name
- NCT06488209
- Testing
- LAD191
- Where
- 3 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
This is a Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis.
- Trial name
- NCT04041609
- Testing
- LYR-210
- Where
- 22 sites in Australia, Austria and 3 more
- Volunteers
- 71 people
- Sponsor
- Lyra Therapeutics
Attention Deficit/Hyperactivity Disorder (ADHD)
The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder
The primary objective of this trial is to determine whether an oral administration of Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children suffering from ADHD.
- Trial name
- NCT00418184
- Testing
- Phosphatidylserine-Omega3, Colored cellulose tainted with fishy odor
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Enzymotec
Cardiovascular Diseases
A First-in-human Study of YN001 in Healthy Volunteers
This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.
- Trial name
- NCT05635084
- Testing
- YN001
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beijing Inno Medicine Co., Ltd.
Hypertension
Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)
ACEis are among the most widely used classes of antihypertensive drugs. ARBs have a similar antihypertensive efficacy and protective effect as ACEis, albeit with a somewhat different mechanism for RAS inhibition and a smaller…
- Trial name
- NCT06990204
- Testing
- Azilsartan medoxomil 80 mg tablet, Edarbi® 80 mg tablets
- Where
- Russia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Asthma
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately…
- Trial name
- NCT06829784
- Testing
- TQC2731 injection
- Where
- 101 sites in China
- Volunteers
- 660 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Alzheimer's Disease
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00151333
- Testing
- SRA-333
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease…
- Trial name
- RADICHOL II (NCT00706849)
- Testing
- mipomersen sodium
- Where
- 48 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Kastle Therapeutics, LLC
Asthma, Status Asthmaticus
Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma
The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of…
- Trial name
- NCT00683449
- Testing
- Dose Group 1, Dose Group 2, Dose Group 3
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- MediciNova
Rhinoconjuntivitis
A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense
The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with polimerized…
- Trial name
- NCT02849249
- Testing
- allergovac polimerized (100/100)
- Where
- 5 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Roxall Medicina España S.A
Moderate-to-Severe Atopic Dermatitis
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03989349
- Testing
- Nemolizumab
- Where
- 138 sites in United States, Belgium and 9 more
- Volunteers
- 787 people
- Sponsor
- Galderma R&D
Multiple Myeloma
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants…
- Trial name
- NCT06742138
- Testing
- QL2109, Pomalidomide, Dexamethasone
- Volunteers
- 284 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Dysbiosis, Prophylaxis
Lactobacillus Reuteri DSM 17938 in Gut Microbiota Development in Infant Born by Caesarean Section
The aim of this study is to assess influence of probiotic Lactobacillus reuteri DSM 17938 on formation of gut microbiota in infant born by Caesarean section.
- Trial name
- NCT03675048
- Testing
- BioGaia Protectis drops
- Where
- Russia
- Volunteers
- 97 people
- Sponsor
- BioGaia AB
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers
This is a randomized, double-blind, placebo-controlled, multiple-ascending dose (MAD) study that will evaluate the safety, tolerability and pharmacokinetics (PK) of RO7079901 and the combination of RO7079901 with meropenem in…
- Trial name
- NCT02972255
- Testing
- RO7079901, Meropenem
- Where
- 2 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Cardiovascular Health
Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals.
Terminalia arjuna, commonly known as arjuna, that belongs to the family of Combretaceae. Most clinical and experimental studies for Terminalia arjuna, have suggested that the crude drug possesses anti-ischemic, antioxidant…
- Trial name
- NCT04715126
- Testing
- Oxyjun
- Where
- 4 sites in India
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Stage III Non-small Cell Lung Cancer
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased…
- Trial name
- ARTIA-Lung (NCT05488626)
- Testing
- Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy
- Where
- United States
- Sponsor
- Varian, a Siemens Healthineers Company
Attention Deficit Hyperactivity Disorder
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
The purpose of this study is to demonstrate that atomoxetine is superior to other early standard therapy (any treatment that investigator considers is appropriate to initiate for the treatment of Attention-Deficit/Hyperactivity…
- Trial name
- ADHD LIFE (NCT00447278)
- Testing
- Atomoxetine, Other standard therapy for ADHD
- Where
- 35 sites in Belgium, France and 7 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.